Back to top
more

Puma Biotechnology (PBYI)

(Delayed Data from NSDQ)

$3.22 USD

3.22
357,505

+0.04 (1.26%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $3.22 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Puma (PBYI) Ends Patient Enrollment in Phase III Cancer Trial

by Zacks Equity Research

Puma Biotechnology, Inc. (PBYI) announced that it has completed enrollment of patients in a phase III study to evaluate its lead pipeline candidate PB272 in combination with Xeloda for treatment of third-line HER2-positive metastatic breast cancer.

    Zacks Equity Research

    Are Options Traders Betting on a Big Move in Puma Biotechnology (PBYI) Stock?

    by Zacks Equity Research

    Investors in Puma Biotechnology, Inc. (PBYI) need to pay close attention to the stock based on moves in the options market lately.

      Arpita Dutt headshot

      Key FDA Events to Watch Out for in Jul 2017

      by Arpita Dutt

      Will the FDA follow the advice of its advisory panel and give its nod to Puma's (PBYI) neratinib?

        Zacks Equity Research

        AstraZeneca's Faslodex Recommended by CHMP for 1st Line Use

        by Zacks Equity Research

        AstraZeneca PLC (AZN) announced that the CHMP of the European Medicines Agency has adopted a positive opinion recommending the marketing authorisation of Faslodex for 1st-line treatment for postmenopausal women with HR+ advanced breast cancer.

          Zacks Equity Research

          Puma (PBYI) Stock Surges as Neratinib Nears FDA Approval

          by Zacks Equity Research

          Puma's stock has significantly outperformed the Zacks classified Medical-Biomed/Genetics industry in the year so far after an FDA advisory committee recommended approval for neratinib in May this year.

            Zacks Equity Research

            Pfizer Provides Final Update on Phase II Talazoparib Study

            by Zacks Equity Research

            Pfizer Inc. (PFE) announced data from its phase II study, ABRAZO, which is evaluating talazoparib in advanced breast cancer patients with germline BRCA 1/2 positive (gBRCA+) mutations, showing anti-tumor activity

              Arpita Dutt headshot

              3 Hot Biotech Stocks to Buy in June

              by Arpita Dutt

              While drug pricing will remain a headline risk, here are a few biotech stocks that have performed well YTD and look well-positioned.

                Zacks Equity Research

                Puma Soaring After Neratinib FDA Panel Win, Time to Buy?

                by Zacks Equity Research

                Shares of Puma Biotechnology, Inc. (PBYI) have risen 35% since it announced that an FDA advisory committee recommended the approval of its lead pipeline candidate, neratinib for the treatment of some breast cancers.

                  Zacks Equity Research

                  Will Puma Biotechnology (PBYI) Continue to Surge Higher?

                  by Zacks Equity Research

                  As of late, it has definitely been a great time to be an investor in Puma Biotechnology Inc (PBYI).

                    Zacks Equity Research

                    Puma Biotechnology (PBYI) Jumps: Stock Adds 29.7% in Session

                    by Zacks Equity Research

                    Puma Biotechnology, Inc. (PBYI) moved big last session, as its shares rose over 30% on the day.

                      Zacks Equity Research

                      Are Options Traders Betting on a Big Move in Puma (PBYI) Stock?

                      by Zacks Equity Research

                      Investors in Puma Biotechnology, Inc. (PBYI) need to pay close attention to the stock based on moves in the options market lately.

                        Zacks Equity Research

                        Reasons to Add Puma Biotechnology (PBYI) to Portfolio Now

                        by Zacks Equity Research

                        On May 16, 2017, we issued an updated report on Puma Biotechnology, Inc. (PBYI).

                          Zacks Equity Research

                          Puma (PBYI) Q1 Loss Narrows, Focus Remains on Neratinib

                          by Zacks Equity Research

                          Puma Biotechnology, Inc. (PBYI) reported a first-quarter 2017 loss of $1.97 per share, narrower than the Zacks Consensus Estimate of a loss of $2.08 and the year-ago loss of $2.19.

                            Zacks Equity Research

                            Puma Biotechnology (PBYI) Q1 Earnings: Stock to Disappoint?

                            by Zacks Equity Research

                            Puma Biotechnology, Inc. (PBYI) is expected to report first-quarter 2017 results later this month.

                              Zacks Equity Research

                              Puma (PBYI) Q4 Loss Wider than Expected, Neratinib in Focus

                              by Zacks Equity Research

                              Puma Biotechnology, Inc. (PBYI) reported a fourth-quarter 2016 loss of $2.04 per share (including the impact of stock-based compensation expenses), wider than both the Zacks Consensus Estimate of a loss of $2.02.

                                Zacks Equity Research

                                Puma Biotechnology (PBYI) Q4 Earnings: What's in the Cards?

                                by Zacks Equity Research

                                Puma Biotechnology, Inc. (PBYI) is expected to report fourth-quarter 2016 results next month. The company has a mixed earnings history.

                                  Zacks Equity Research

                                  Puma (PBYI) Expands Study Cohort for Lead Candidate PB272

                                  by Zacks Equity Research

                                  Puma Biotechnology, Inc. (PBYI) has expanded the fourth cohort of the phase II SUMMIT study evaluating its lead candidate PB272 (neratinib) as a single agent in patients with solid tumors who have an activating HER2 mutation (basket study).